Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.69 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.69 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.55 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.55 |
| ▸ | AGXT | P21549 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.45 |
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GLS | O94925 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31362124 | 0.83 | CYP2A6 (0.56) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL1444757 | 0.82 | CYP2A6 (0.59) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL1254283 | 0.81 | CYP2A6 (1.00) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL15980823 | 0.81 | CYP2A6 (0.54) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL6963172 | 0.79 | CYP2A6 (0.60) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL7340276 | 0.79 | CYP2A6 (0.60) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL18650053 | 0.79 | CYP2A6 (0.51) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL4961407 | 0.78 | CYP2A6 (0.69) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL15984841 | 0.78 | TAAR1 (0.44) | CYP2A6ADRB2ASIC3LOXL2TAAR1 | |
| SCHEMBL30756777 | 0.78 | CYP2A6 (0.50) | CYP2A6ADRB2ASIC3LOXL2AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015106294-A1 | BIVALENT BCR-ABL TYROSINE KINASE LIGANDS, AND METHODS OF USING SAME | COFERON,INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015081284-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2013033268-A2 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | BRDT, BRD2, BRD4 | CYP2A6 4717/4885ADRB2 3401/4885ASIC3 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.